InterMune is expected to report results in their Idiopathic Pulmonary Fibrosis (IPF) study CAPACITY of the drug Pirfenidone. It was approved in Japan in October of this year #msg-32898098 and recently launched #msg-34138706. IPF does not have any current approved therapies (NAC, steroids and some other agents are used to try to halt progression with mixed results and no SOC). The CAPACITY program is actually two studies http://clinicaltrials.gov/ct2/show/NCT00287716, http://clinicaltrials.gov/ct2/show/NCT00287729 ), what do you think? Please take the survey.
What will the outcome of the CAPACITY trials show? 1. Positive results (Both trials p < .05 on FVC and at least PFS trending) 2. Mixed results (e.g. One trial positive but not both, both positive but no PFS, several secondaries positive but trend only on primary) 3. Negative results (No FVC, no PFS, no meaningful trends, IPF is the graveyard rkrw warns about)
Market Data 
Markets 
AI
